Business
Galmed Issues CEO Letter to Shareholders
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer.
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer.","length":348,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"Galmed Pharmaceuticals Ltd. Logo","displaySize":"","headline":null,"caption":"Galmed Pharmaceuticals Ltd. Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rkpv_HpbOjVKPN_v6KG17Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e","width":400,"height":95}}},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"Dear Shareholders,","length":18,"tagName":"p"},{"type":"text","content":"I'm reaching out today to share the bigger picture and highlight the exciting momentum building at Galmed. With significant recent achievements and ambitious plans ahead, this is an ideal time to connect the dots on our progress and reaffirm our vision for a transformative future. As we connect the dots on our progress, I'm excited to reaffirm the strength of Galmed and the incredible opportunities that lie ahead.","length":425,"tagName":"p"},{"type":"text","content":"Over the past year, we have successfully expanded our therapeutic focus beyond liver disease, generating compelling new data that supports a broader clinical development path for Aramchol in oncology and cardiometabolic indications. Our fundamentals remain solid, our scientific achievements continue to accelerate, and our strategy is firmly focused on short and long-term value creation.","length":389,"tagName":"p"},{"type":"text","content":"My message to investors is clear: Galmed is well-capitalized, scientifically advancing on multiple fronts, and positioned for meaningful growth opportunities.","length":158,"tagName":"p"},{"type":"text","content":"1. Strong Cash Position and Prudent Financial Stewardship ","length":57,"tagName":"p"},{"type":"te...